Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Designing antibodies as therapeutics
Paul J. Carter, Arvind Rajpal
Cell (2022) Vol. 185, Iss. 15, pp. 2789-2805
Open Access | Times Cited: 124

Showing 26-50 of 124 citing articles:

FLAb: Benchmarking deep learning methods for antibody fitness prediction
Michael Chungyoun, Jeffrey A. Ruffolo, Jeffrey J. Gray
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Liquid Droplet-Mediated Formulation of Lipid Nanoparticles Encapsulating Immunoglobulin G for Cytosolic Delivery
Yusuke Hirai, Yoshimasa Kawaguchi, Chisato Kasahara, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 4, pp. 1653-1661
Closed Access | Times Cited: 5
A new era of antibody discovery: an in-depth review of AI-driven approaches
Jin Cheng, Tianjian Liang, Xiang‐Qun Xie, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 6, pp. 103984-103984
Closed Access | Times Cited: 5
A comparison of antibody–antigen complex sequence‐to‐structure prediction methods and their systematic biases
Katherine Maia McCoy, Margaret E. Ackerman, Gevorg Grigoryan
Protein Science (2024) Vol. 33, Iss. 9
Open Access | Times Cited: 5
Cryo-electron microscopy-based drug design
Ecenur Cebi, Joohyun Lee, Vinod Kumar Subramani, et al.
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access | Times Cited: 4
Nano/genetically engineered cells for immunotherapy
Jingrui Shen, Yang Zhou, Lichen Yin
BMEMat (2024)
Open Access | Times Cited: 4
Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling
Chiara Lebon, Sebastian Großmann, Greg Mann, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
“Stapling” scFv for multispecific biotherapeutics of superior properties
Lauren Boucher, Elisabeth Geyer Prinslow, Michael Feldkamp, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Human GST P1-1 Redesigned for Enhanced Catalytic Activity with the Anticancer Prodrug Telcyta and Improved Thermostability
Aram Ismail, Sridhar Govindarajan, Bengt Mannervik
Cancers (2024) Vol. 16, Iss. 4, pp. 762-762
Open Access | Times Cited: 3
Structural insights into IL-6 signaling inhibition by therapeutic antibodies
Mingxing Wang, Long Chen, Jin He, et al.
Cell Reports (2024) Vol. 43, Iss. 3, pp. 113819-113819
Open Access | Times Cited: 3
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Longchao Liu, Jiahui Chen
Medical Review (2022) Vol. 2, Iss. 6, pp. 555-569
Open Access | Times Cited: 16
Identification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma
Silin Jiang, Yuxiang Dong, Jun Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Phage display assisted discovery of a pH‐dependent anti‐α‐cobratoxin antibody from a natural variable domain library
Tulika Tulika, Rasmus W. Pedersen, Charlotte Rimbault, et al.
Protein Science (2023) Vol. 32, Iss. 12
Open Access | Times Cited: 8
An integrated methodology for quality assessment of therapeutic antibodies with potential long circulation half-life in harvested cell culture fluid using FcRn immobilized hydrophilic magnetic graphene
Jianan Feng, Hao Cao, Yangjiayi Xiang, et al.
Talanta (2024) Vol. 272, pp. 125781-125781
Closed Access | Times Cited: 2
In Migratio Noncovalent Fluorophore Labeling of Proteins by Propidium Iodide in Sodium Dodecyl Sulfate Capillary Gel Electrophoresis
Felícia Auer, András Guttman
Analytical Chemistry (2024) Vol. 96, Iss. 27, pp. 10969-10977
Closed Access | Times Cited: 2
Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity
Qian‐Ni Ye, Long Zhu, Jie Liang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
Itzel Condado Morales, Fabian Dingfelder, Isabel Waibel, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
Paul J. Carter, Valerie Quarmby
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 12, pp. 898-913
Closed Access | Times Cited: 2
Study on antibody Fc-glycosylation for optimal effector functions
Vidya S. Shivatare, Po‐Kai Chuang, Tzu‐Hao Tseng, et al.
Chemical Communications (2023) Vol. 59, Iss. 37, pp. 5555-5558
Closed Access | Times Cited: 7
Revolutionizing antiviral therapy with nanobodies: Generation and prospects
Mujahed I. Mustafa, Ahmed Mohammed
Biotechnology Reports (2023) Vol. 39, pp. e00803-e00803
Open Access | Times Cited: 7
Two antibodies show broad, synergistic neutralization against SARS-CoV-2 variants by inducing conformational change within the RBD
Hui Sun, Tingting Deng, Yali Zhang, et al.
Protein & Cell (2023) Vol. 15, Iss. 2, pp. 121-134
Open Access | Times Cited: 6
Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review
Zhengbin Zhang, Liwen Zhu, Ziqian Wang, et al.
Progress in Lipid Research (2023) Vol. 91, pp. 101240-101240
Closed Access | Times Cited: 6
Position-Specific Enrichment Ratio Matrix scores predict antibody variant properties from deep sequencing data
Matthew D. Smith, Marshall Case, Emily K. Makowski, et al.
Bioinformatics (2023) Vol. 39, Iss. 9
Open Access | Times Cited: 6
Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants
Robert Pejchal, Anthony B. Cooper, Michael E. Brown, et al.
Antibodies (2023) Vol. 12, Iss. 3, pp. 54-54
Open Access | Times Cited: 6
Long-Acting Strategies for Antibody Drugs: Structural Modification, Controlling Release, and Changing the Administration Route
Hao Wang, Mengdi Song, Jiaqi Xu, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2024) Vol. 49, Iss. 3, pp. 295-316
Closed Access | Times Cited: 1

Scroll to top